About Zinc finger protein 782
Zinc finger protein 782 (ZNF782) is a protein
from Homo sapiens identified by UniProt accession
Q6ZMW2, 699 residues long.
MolForge cross-references it against 0 known binders and
5 disease associations.
Target properties
| Protein name | Zinc finger protein 782 |
| UniProt accession | Q6ZMW2 |
| Gene | ZNF782 |
| Organism | Homo sapiens |
| Length | 699 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (5)
Diseases linked to this target (Open Targets).
- mean reticulocyte volume · score 0.03
- mean corpuscular volume · score 0.02
- body height · score 0.02
- neoplasm · score 0.00
- gastric carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6ZMW2-F1 | alphafold | PREDICTED | 60.67 | — |
Amino-acid sequence (699 residues)
MNTFQASVSF QDVTVEFSQE EWQHMGPVER TLYRDVMLEN YSHLVSVGYC FTKPELIFTL EQGEDPWLLE KEKGFLSRNS PEDSQPDEIS EKSPENQGKH LLQVLFTNKL LTTEQEISGK PHNRDINIFR ARMMPCKCDI AGSACQGLSL MAPHCQYSKE KAHERNVCDK WLISIKDGRT NTQEKSFAYS KIVKTLHHKE EVIQHQTIQT LGQDFEYNES RKAFLEKAAL VTSNSTHPKG KSYNFNKFGE NKYDKSTFII PQNMNPEKSH YEFNDTGNCF CRITHKTLTG GKSFSQKSHI REHHRVHIGV KPFEYGKSFN RNSTLPVHQR THATDKYSDY HPCTETFSYQ STFSVHQKVH IRAKPYEYNE CGKSCSMNSH LIWPQKSHTG EKPYECPECG KAFSEKSRLR KHQRTHTGEK PYKCDGCDKA FSAKSGLRIH QRTHTGEKPF ECHECGKSFN YKSILIVHQR THTGEKPFEC NECGKSFSHM SGLRNHRRTH TGERPYKCDE CGKAFKLKSG LRKHHRTHTG EKPYKCNQCG KAFGQKSQLR GHHRIHTGEK PYKCNHCGEA FSQKSNLRVH HRTHTGEKPY QCEECGKTFR QKSNLRGHQR THTGEKPYEC NECGKAFSEK SVLRKHQRTH TGEKPYNCNQ CGEAFSQKSN LRVHQRTHTG EKPYKCDKCG RTFSQKSSLR EHQKAHPGD
Explore Zinc finger protein 782 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets